Search

Metallic nanoparticles have been utilized as an analytical tool to detecting a wide variety of organic analytes. Among them, gold nanoparticles demonstrating outstanding surface plasmonic resonance property have been well recognized and received wide attention for plasmon-based sensing applications. However, in literature, gold-based nanosensor has to be integrated with specific “ligand” molecule in order to gain molecular recognition ability. However, “ligand” molecules, included proteins, peptides, nucleic acids, etc. are expensive and vulnerable to environmental change, in the meantime, anchoring procedure of the “ligand” molecules to gold surface may be cost-ineffective and endangered to the ligand′s activity, making a final analytic probe less reliable and risk in production capability. Here, we develop a new approach by designing a colloid-type sensor using a few “bare” Au nanorods deposited on the surface of a colloidal chitosan carrier. By tuning the solution pH, the resulting colloidal nanoprobe is capable of detecting proteins, i.e., human serum albumin and lysozyme, with high specificity and sensitivity. This new approach allows a new type of the molecular probes to be well manipulated to monitor important biomolecules for medical detection, diagnosis, and bioengineering applications.

Chitosan is among the most abundant biopolymers on earth and has been either used orexhibited potential in a wide variety of industrial and biomedical applications. With theadvancement of materials technologies, chitosan has been chemically modified to self-assemble into nanoarchitectures that are usable in advanced biomedical applications, suchas drug nanocarriers, macroscopic injectables, tissue-engineering scaffolds, and nanoimag-ing agents. Colloidal amphiphilically modified chitosan (AMC) is a relatively recent materialreceiving increased attention with numerous publications addressing the medical advan-tages of specific systems. To date, many reviews have focused on the synthesis andbiomedical properties of chitosan-based biomaterials, but a comprehensive study focusingon the colloidal properties of AMC in relation to biomedical performance appears to be lack-ing. This review provides a survey of the field, critically reviewing the colloidal propertiesand biomedical performance of AMC systems, such as nanoparticle drug delivery systemsand macroscopic medical devices. Finally, the future development, market potential, andclinical implications of these promising colloidal-structured biomaterials are summarised. Refereed/Peer-reviewed

Diabetes is a common global disease that causes immense suffering for individuals and huge costs for the health care system. To minimize complications such as organ degeneration, diabetic patients are required to undergo treatments to maintain the blood glucose level in the normal range, ideally mimicking normal insulin secretion. The normal physiological insulin secretion pattern in healthy individuals consists of a base (basal) level through the day and increased secretion after meals (bolus insulin). Thus effective treatments may combine long acting, low-level insulin therapy with boosts of short acting insulin and/or oral agents. To achieve long term management of basal insulin level, an injectable insulin-loaded gel composed of self-assembled nanoparticles from carboxymethyl-hexanoyl chitosan (CHC) and integrated lysozyme for controlled biodegradation and insulin release was developed. In vitro characterizations and evaluations confirmed that lysozyme was active on CHC and that the amount of lysozyme in a CHC hydrogel determined the degradation and insulin release rate. The degradation products were found to be highly cytocompatible using a cell assay. In vivo evaluation of the system in a diabetic mouse model revealed that the fasted blood glucose level could be maintained in the normal range for 10 days with a single injection of insulin-loaded CHC-lysozyme gel. The insulin-loaded CHC-lysozyme gels clearly show promise for use as a novel injectable long-acting insulin delivery system, with potential to manage the basal insulin level for many days with a single injection. Refereed/Peer-reviewed

Hydrogels composed of assembled colloids is a material class that is currently receiving much interest and shows great promise for use in biomedical applications. This emerging material class presents unique properties derived from the combination of nanosized domains in the form of colloidal particles with a continuous gel network and an interspersed liquid phase. Here we developed an amphiphilic chitosanbased, thermogelling, shear-reversible colloidal gel system for improved glaucoma treatment and addressed how preparation procedures and loading with the anti-glaucoma drug latanoprost and commonly used preservative benzalkonium chloride influenced the mechanical properties of and drug release from the colloidal gels. The results highlight that incorporated substances and preparation procedures have effects both on mechanical properties and drug release, but that the release of drug loaded in the colloidal carriers is mainly limited by transport out of the carriers, rather than by diffusion within the gel. The developed colloidal chitosan based gels hold outstanding biomedical potential, as confirmed by the ease of preparation and administration, low cytotoxicity in MTT assay, excellent biocompatibility and lowering of intraocular pressure for 40 days in a rabbit glaucoma model. The findings clearly justify further investigations towards clinical use in the treatment of glaucoma. Furthermore, the use of this shear-reversible colloidal gel could easily be extended to localized treatment of a number of critical conditions, from chronic disorders to cancer, potentially resulting in a number of new therapeutics with improved clinical performance. Refereed/Peer-reviewed

Thermo-gelling injectable nanogels, with no burst release of loaded drug, were prepared by a simple route by combining self assembled nanocapsules of amphiphilically modified chitosan with glycerophosphate di-sodium salt and glycerol. The potential as a depot drug delivery system was demonstrated in vivo through the therapeutic effect of ethosuximide (ESM) loaded nanogels, suppressing spike wave discharges (SWDs) in Long Evan rat model. Simultaneously clearance of gels from the site of administration was monitored non-invasively using MRI. The gel structure was characterized using TEM and SEM, confirming the gels to be an assembly of nanocapsules and using two-photon microscopy to visualize the network structure. In vitro drug release studies using ESM revealed that the nanogels exhibited extended, mostly Fickian release. Finally, all investigated formulations displayed excellent cytotoxicity data determined by MTT assay using human retinal pigmented epithelium cells. All presented properties are highly desirable for injectable depot gels for drug delivery. Refereed/Peer-reviewed